 Connection
John Imig to Drug Evaluation, Preclinical
This is a "connection" page, showing publications John Imig has written about Drug Evaluation, Preclinical.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.282 |
|
|
|
-
Imig JD. Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. Pharmacol Ther. 2018 12; 192:1-19.
Score: 0.152
-
Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, Newman JW, Luria A, Hammock BD, Imig JD. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond). 2009 Jan; 116(1):61-70.
Score: 0.079
-
Kim J, Yoon SP, Toews ML, Imig JD, Hwang SH, Hammock BD, Padanilam BJ. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. Am J Physiol Renal Physiol. 2015 Jan 15; 308(2):F131-9.
Score: 0.030
-
Cert?kov? Ch?bov? V, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerov? Z, Vanourkov? Z, Kopkan L, Kramer HJ, Falck JR, Imig JD, Hammock BD, Vaneckov? I, Cervenka L. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci (Lond). 2010 Feb 23; 118(10):617-32.
Score: 0.021
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|